CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply Journal Article

  

Authors:	Wunder, J. S.; Nielsen, T. O.; Maki, R. G.; O'Sullivan, B.; Alman, B. A.
Article Title:	CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply
Keywords:	osteosarcoma; treatment outcome; bone neoplasms; polymorphism, single nucleotide; cisplatin; unspecified side effect; methotrexate; antineoplastic agent; letter; metastasis; breast cancer; gene expression; genetic association; genetic variability; genotype; prediction; high risk patient; docetaxel; sarcoma; drug response; glutathione transferase; drug clearance; drug metabolism; pharmacogenetics; hearing impairment; genetic polymorphism; mitochondrial dna; ototoxicity; genetic correlation; thymine; cytochrome p450 3a4; 5,10 methylenetetrahydrofolate reductase (fadh2); cytochrome p450 3a5; cytochrome p-450 enzyme system
Journal Title:	Lancet Oncology
Volume:	8
Issue:	8
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2007-08-01
Start Page:	668
End Page:	669
Language:	English
DOI:	10.1016/s1470-2045(07)70216-4
PUBMED:	17679079
PROVIDER:	scopus
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-34547588354&partnerID=40&md5=67ac510e739c4b866b296378b0ab4c6b
Notes:	--- - "Export Date: 17 November 2011" - "CODEN: LOANB" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/18501